Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.58 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706517 | 1.00 | FKBP1A (0.58) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2679494 | 1.00 | FKBP1A (0.58) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1784260 | 0.99 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9251636 | 0.99 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28351585 | 0.84 | FKBP1A (0.67) | FKBP1APREP | |
| SCHEMBL13148433 | 0.84 | FKBP1A (0.57) | FKBP1APREPSMN1; SMN2 | |
| SCHEMBL13413549 | 0.84 | FKBP1A (0.57) | FKBP1APREPSMN1; SMN2 | |
| SCHEMBL13099455 | 0.84 | FKBP1A (0.60) | FKBP1APREP | |
| SCHEMBL27553714 | 0.84 | FKBP1A (0.57) | FKBP1APREPNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12869918 | 0.84 | FKBP1A (0.60) | FKBP1APREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109414402-B | Method for preparing a drug delivery system with a testosterone compound present externally or topically and such a drug delivery system | EB IP希博里塔布斯有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9670186-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9487514-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9181206-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150158819-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-11 | — | — | US | disclosed |
| US-9045443-B2 | Nitric oxide donor neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150133658-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-14 | — | — | US | disclosed |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-01 | — | — | US | disclosed |
| CN-101896470-B | Dual-acting benzimidazole derivatives and their use as antihypertensive agents | THERAVANCE INC | 2013-04-10 | — | — | CN | disclosed |
| US-8372984-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| CN-101675036-B | Dual-effect benzimidazole antihypertensive agents | THERAVANCE INC | 2013-01-02 | — | — | CN | disclosed |
| US-8338418-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-5674905-A | ADMINISTERING AS GASTRIN OR CHOLECYSTOKININ ANTAGONISTS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-10-07 | — | — | US | disclosed |
| EP-0655053-B1 | BICYCLOOCTANE AND BICYCLOHEPTANE DERIVATIVES | BLACK JAMES FOUNDATION (GB) | 1997-09-03 | — | — | EP | disclosed |
| EP-0655053-A1 | BICYCLOOCTANE AND BICYCLOHEPTANE DERIVATIVES. | BLACK JAMES FOUNDATION (GB) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994000421-A1 | BICYCLOOCTANE AND BICYCLOHEPTANE DERIVATIVES | JAMES BLACK FOUNDATION LIMITED (GB) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133658-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | FKBP1A 3447/4885PREP 27/4885NPC1 233/4885 |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FKBP1A 2960/4885PREP 11/4885NPC1 312/4885 |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FKBP1A 3044/4885PREP 9/4885NPC1 476/4885 |
| US-20150158819-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | FKBP1A 3449/4885PREP 12/4885NPC1 186/4885 |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | FKBP1A 4202/4885PREP 246/4885NPC1 1762/4885 |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | FKBP1A 3196/4885PREP 99/4885NPC1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.